06.13.19
Camargo Pharmaceutical Services, a drug development and commercialization partner, will acquire InSymbiosis, a Canadian drug development company, to improve how biopharma companies outsource R&D.
InSymbiosis was founded in 2005, and is managed by ex-pharma and contract research organization drug development scientists and executives. Based in Montreal, the team includes a multidisciplinary drug development group, financial and investment experts, and a strong project management team.
Earlier this year, Camargo announced plans to expand capabilities and enhance its global presence both organically and through acquisitions.
"Together, we strengthen our ability to help clients reach critical milestones and connect patients to life-changing therapies faster," said Camargo chief executive officer, Dan Duffy. "InSymbiosis provides powerful results for clients looking to optimize their nonclinical and clinical development programs. Combined with Camargo's expertise in drug development strategy and regulatory services, this acquisition accelerates our efforts to deliver an industry-leading integrated drug development solution for the global pharma and biotech market."
"We started InSymbiosis with a vision to create symbiotic relationships across the healthcare landscape that drive pharmaceutical development forward," said InSymbiosis chief executive officer, Dean Wenham, Ph.D. "Together with Camargo, we deepen our ability to build and advance these relationships and deliver optimized development programs for our clients."
InSymbiosis was founded in 2005, and is managed by ex-pharma and contract research organization drug development scientists and executives. Based in Montreal, the team includes a multidisciplinary drug development group, financial and investment experts, and a strong project management team.
Earlier this year, Camargo announced plans to expand capabilities and enhance its global presence both organically and through acquisitions.
"Together, we strengthen our ability to help clients reach critical milestones and connect patients to life-changing therapies faster," said Camargo chief executive officer, Dan Duffy. "InSymbiosis provides powerful results for clients looking to optimize their nonclinical and clinical development programs. Combined with Camargo's expertise in drug development strategy and regulatory services, this acquisition accelerates our efforts to deliver an industry-leading integrated drug development solution for the global pharma and biotech market."
"We started InSymbiosis with a vision to create symbiotic relationships across the healthcare landscape that drive pharmaceutical development forward," said InSymbiosis chief executive officer, Dean Wenham, Ph.D. "Together with Camargo, we deepen our ability to build and advance these relationships and deliver optimized development programs for our clients."
